ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Pharmaceuticals

South Korea's Celltrion exports coronavirus tests to US

Diagnostic kits to help fill US testing gap

Celltrion has been developing testing kits and a treatment for the coronavirus. (Photo courtesy of Celltrion)

SEOUL -- South Korea's Celltrion has started selling coronavirus screening kits in the U.S. to help bridge the country's testing gap, the company said Wednesday.

The Incheon-based drugmaker expects both its antigen and antibody testing kits to be approved for sale in the U.S. by mid-August. A U.S. subsidiary will distribute the kits.

The number of COVID-19 infections in South Korea is limited to dozens of people a day. But in the U.S., the infection rate is much worse and there is a shortage of antigen testing kits. Celltrion will capture the strong demand for diagnostic kits with its products.

The antigen test determines coronavirus infection in a shorter amount of time than a PCR test, which uses the polymerase chain reaction method to detect the virus's genetic material. The antibody test shows if someone has been infected with the coronavirus in the past.

Celltrion developed the two kits along with domestic peer BBB. Celltrion plans to expand exports to Europe and other places after winning approval in those places.

The South Korean government is supporting the export of diagnostic kits. Celltrion says it will take the lead in supplying countries in Southeast Asia, Africa and South America where medical supplies tend to run short.

Apart from the testing kits, Celltrion is busy developing a treatment for the novel coronavirus. The company has partnered with Seoul National University's medical college and other schools to analyze the blood of COVID-19 patients with the goal of developing a candidate to suppress the activity of the virus.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more